



Pfizer Shares Pre-Clinical Data Updates on COVID-19 Antiviral Research Program

Wednesday, July 22, 2020 - 06:36pm

New York, July 10, 2020 – Pfizer today issued an update on the company’s pre-clinical research efforts focused on developing a potential antiviral treatment for COVID-19. These updates are part of the company’s commitment to transparency in research findings related to COVID-19, as set forth in Pfizer’s five-point plan for the biopharmaceutical industry to tackle the disease caused by the novel coronavirus.

Today, we shared the chemical structure of a 3C-like (3CL) protease inhibitor and its in vitro activity against coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The structure and data can be found in a manuscript posted to the preprint server ChemRxiv and on Pfizer.com. This manuscript is concurrently undergoing scientific peer review for potential publication.

In addition, SARS-CoV-1 3CL protease inhibition data on 76 compounds and their molecular structures from the same chemical series as the lead 3CL protease inhibitor has been posted on Pfizer.com as part of our commitment to open data sharing.

“We’re pleased that our research efforts continue to progress and we are learning more about the potential of protease inhibitors to address infections caused by coronaviruses,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development, and Medical. “As part of our focused efforts to provide potential treatment options for COVID-19, we are encouraged by the initial data and we will continue to assess the suitability of this class of drugs for IV administration clinically. One of our 3CL protease inhibitors could be the first protease inhibitor to enter clinical studies for evaluation of treating COVID-19, with a potential clinical study start in the third quarter of this year pending regulatory feedback. We are also exploring, via in vitro studies,

potential COVID-19 combination therapies that combine our protease inhibitors with other antiviral compounds.”

About Pfizer: Breakthroughs that change patients’ lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).